BIIB's TRANSCEND phase III study on felzartamab in adult kidney transplant recipients diagnosed with late AMR is set to enroll approximately 120 patients.

Artificial intelligence (AI) and the Internet of Things (IoT) are about to revolutionize the biopharmaceutical industry.

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

After 2 positive trials, low-dose colchicine’ got the FDA nod for CV reduction but then the CLEAR SYNERGY trial found no ...

UK-based Purespring Therapeutics, a pioneering company focused on transforming the treatment of kidney diseases, today ...

In the trials, omalizumab and multi-allergen oral immunotherapy showed alike efficacy in protecting against food allergies, ...

Haseeb Ahmad brings over 25 years of leadership experience in life sciences, most recently serving as President of Novartis ...

Over the last 30 years in the neurotoxins market, Ipsen has established itself as one of the leading players in neurosciences, successfully driving research, clinical development and growth based on ...

Glenmark Pharma has appointed Starcom for the media mandate of one of its brands, sources have confirmed to e4m. Further ...

Zevra Therapeutics, Inc. ( NASDAQ: ZVRA) Q4 2024 Earnings Conference Call March 11, 2025 4:30 PM ET Nichol Ochsner - VP, IR and Corporate Communications Neil McFarlane - President and CEO LaDuane ...

Klinger joined the Cambridge, Massachusetts-based pharmaceutical company in 2021, when Moderna's stock was trading at around ...